Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Date | Friday, March 21, 2025 |
| Time | 10:00 AM Eastern Time |
| Dial In Numbers | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on and .
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
SOURCE: Biofrontera Inc.
